These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 10364775)

  • 21. Treatment of symptomatic venous thromboembolism: improving outcomes.
    Büller HR
    Semin Thromb Hemost; 2002 Jun; 28 Suppl 2():41-8. PubMed ID: 12073179
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Management of venous thromboembolism: a systematic review for a practice guideline.
    Segal JB; Streiff MB; Hofmann LV; Thornton K; Bass EB
    Ann Intern Med; 2007 Feb; 146(3):211-22. PubMed ID: 17261856
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy of a low molecular weight heparin administered intravenously or subcutaneously in comparison with intravenous unfractionated heparin in the treatment of deep venous thrombosis. Certoparin-Study Group.
    Kirchmaier CM; Wolf H; Schäfer H; Ehlers B; Breddin HK
    Int Angiol; 1998 Sep; 17(3):135-45. PubMed ID: 9821025
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Therapeutic indications for acute venous thromboembolism. Current status and future perspectives].
    Prandoni P; Simioni P; Pagnan A
    Minerva Cardioangiol; 2003 Aug; 51(4):361-71. PubMed ID: 12900718
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of low-molecular-weight heparin, administered primarily at home, with unfractionated heparin, administered in hospital, and subcutaneous heparin, administered at home for deep-vein thrombosis.
    Belcaro G; Nicolaides AN; Cesarone MR; Laurora G; De Sanctis MT; Incandela L; Barsotti A; Corsi M; Vasdekis S; Christopoulos D; Lennox A; Malouf M
    Angiology; 1999 Oct; 50(10):781-7. PubMed ID: 10535716
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Treatment and prophylaxis of deep venous thrombosis with low molecular weight heparins (meta-analysis of clinical trials)].
    Valiukiene L; Naudziūnas A; Unikauskas A
    Medicina (Kaunas); 2003; 39(4):352-8. PubMed ID: 12738903
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Low-molecular-weight heparin in the treatment of venous thromboembolism.
    Hull RD; Pineo GF
    Semin Thromb Hemost; 2000; 26 Suppl 1():61-7. PubMed ID: 11011809
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tinzaparin sodium: a review of its pharmacology and clinical use in the prophylaxis and treatment of thromboembolic disease.
    Cheer SM; Dunn CJ; Foster R
    Drugs; 2004; 64(13):1479-502. PubMed ID: 15212562
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Heparins and venous thromboembolism: current practice and future directions.
    Prandoni P
    Thromb Haemost; 2001 Jul; 86(1):488-98. PubMed ID: 11487039
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolism.
    van Den Belt AG; Prins MH; Lensing AW; Castro AA; Clark OA; Atallah AN; Burihan E
    Cochrane Database Syst Rev; 2000; (2):CD001100. PubMed ID: 10796593
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Low-molecular-weight heparin in the treatment of deep venous thrombosis.
    Hauer KE
    West J Med; 1998 Oct; 169(4):240-4. PubMed ID: 9795594
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment of venous thromboembolism with low-molecular-weight heparin: a synthesis of the evidence published in systematic literature reviews.
    Krishnan JA; Segal JB; Streiff MB; Bolger DT; Eng J; Jenckes MW; Tamariz LJ; Bass EB
    Respir Med; 2004 May; 98(5):376-86. PubMed ID: 15139566
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Venous thromboembolism, thrombophilia, antithrombotic therapy, and pregnancy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).
    Bates SM; Greer IA; Pabinger I; Sofaer S; Hirsh J
    Chest; 2008 Jun; 133(6 Suppl):844S-886S. PubMed ID: 18574280
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Low-molecular-weight heparins in the treatment of deep-vein thrombosis.
    Martineau P; Tawil N
    Ann Pharmacother; 1998 May; 32(5):588-98, 601. PubMed ID: 9606481
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Fixed-dose, body weight-independent subcutaneous LMW heparin versus adjusted dose unfractionated intravenous heparin in the initial treatment of proximal venous thrombosis. EASTERN Investigators.
    Harenberg J; Schmidt JA; Koppenhagen K; Tolle A; Huisman MV; Büller HR
    Thromb Haemost; 2000 May; 83(5):652-6. PubMed ID: 10823256
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of fixed-dose weight-adjusted unfractionated heparin and low-molecular-weight heparin for acute treatment of venous thromboembolism.
    Kearon C; Ginsberg JS; Julian JA; Douketis J; Solymoss S; Ockelford P; Jackson S; Turpie AG; MacKinnon B; Hirsh J; Gent M;
    JAMA; 2006 Aug; 296(8):935-42. PubMed ID: 16926353
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Low-molecular weight heparins in venous and arterial thrombotic disease.
    Bijsterveld NR; Hettiarachchi R; Peters R; Prins MH; Levi M; Büller HR
    Thromb Haemost; 1999 Sep; 82 Suppl 1():139-47. PubMed ID: 10695506
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Home versus in-patient treatment for deep vein thrombosis.
    Schraibman IG; Milne AA; Royle EM
    Cochrane Database Syst Rev; 2001; (2):CD003076. PubMed ID: 11406067
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Selecting an anticoagulant for recurrent venous thromboembolism in cancer.
    Goodin S
    Am J Health Syst Pharm; 2005 Nov; 62(22 Suppl 5):S10-3. PubMed ID: 16286363
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Management of venous thromboembolism: optimization by clinical trials.
    Turpie AG
    Haemostasis; 1996 Oct; 26 Suppl 4():220-6. PubMed ID: 8979127
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.